The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of
patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin
analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on
more than 90 % of medullary thyroid carcinomas.
In the pilot (phase 0) study investigators will correlate the tumour detection rate with the
surgery and histology (proof of concept study). Furthermore, kidney protection and dosimetry
studies will be performed in order to determine the kidney protection protocol and starting
activity for the dose escalation study in the following, dose escalation (phase I) study. In
the phase I study investigators will determinate the maximum tolerated dose of 177Lu-PP-F11N
in patients with MTC. Furthermore, correlation with tumour radiation dose and treatment
response as well as organ radiation doses and maximal tolerated dose will be performed in
order to allow prospective individual patient tailored therapy planning.